A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Clinical trial NCT03500380 · UNKNOWN

Trial details

NCT number: NCT03500380
Sponsor: RemeGen Co., Ltd.
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms Breast Diseases Capecitabine HER2-positive Breast Cancer HER2 Positive Breast Carcinoma HER2-positive Advanced Breast With Liver Metastases

Start date: 2018-04-24
Primary completion: 2024-07-31
Enrollment: 301

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.